(IRWD) Ironwood Pharmaceuticals - Overview
Stock: Linaclotide, Apraglutide, IW-3300
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 102% |
| Relative Tail Risk | -20.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.17 |
| Alpha | 90.46 |
| Character TTM | |
|---|---|
| Beta | 0.974 |
| Beta Downside | 1.066 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.33% |
| CAGR/Max DD | -0.28 |
Description: IRWD Ironwood Pharmaceuticals January 18, 2026
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a U.S.-based biotech that commercializes linaclotide, a guanylate cyclase-C agonist sold as LINZESS (adult IBS-C/chronic idiopathic constipation) and CONSTELLA (pediatric functional constipation), and is advancing a pipeline that includes IW-3300 for visceral-pain disorders and Apraglutide for short-bowel syndrome and acute graft-versus-host disease.
The firm leverages strategic alliances with AbbVie, AstraZeneca and Astellas to co-develop and co-market linaclotide, extending its reach beyond the United States. 2023 linaclotide net sales were roughly $1.0 billion, giving Ironwood a cash runway of about $300 million and a net loss of $150 million, reflecting heavy R&D spend. The global gastrointestinal-therapeutics market is projected to expand at a 5 % CAGR through 2028, providing a favorable backdrop for both existing products and pipeline candidates.
Given the company’s reliance on a single commercial product and the binary nature of upcoming regulatory milestones for IW-3300 and Apraglutide, investors should monitor FDA decision dates and partnership revenue-share terms as key risk drivers. For a deeper, data-driven valuation framework, you may find ValueRay’s analyst notes worth a look.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 28.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA -14.71 > 1.0 |
| NWC/Revenue: 9.25% < 20% (prev 34.15%; Δ -24.90% < -1%) |
| CFO/TA 0.17 > 3% & CFO 67.7m > Net Income 28.5m |
| Net Debt (457.8m) to EBITDA (146.9m): 3.12 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.8m) vs 12m ago 10.94% < -2% |
| Gross Margin: 68.62% > 18% (prev 0.85%; Δ 6777 % > 0.5%) |
| Asset Turnover: 86.30% > 50% (prev 97.15%; Δ -10.85% > 0%) |
| Interest Coverage Ratio: 4.29 > 6 (EBITDA TTM 146.9m / Interest Expense TTM 33.8m) |
Altman Z'' -13.42
| A: 0.08 (Total Current Assets 273.8m - Total Current Liabilities 242.5m) / Total Assets 396.1m |
| B: -4.22 (Retained Earnings -1.67b / Total Assets 396.1m) |
| C: 0.37 (EBIT TTM 145.0m / Avg Total Assets 392.8m) |
| D: -2.53 (Book Value of Equity -1.67b / Total Liabilities 660.2m) |
| Altman-Z'' Score: -13.42 = D |
Beneish M -2.62
| DSRI: 1.76 (Receivables 120.4m/76.2m, Revenue 339.0m/378.4m) |
| GMI: 1.24 (GM 68.62% / 85.03%) |
| AQI: 0.55 (AQ_t 0.27 / AQ_t-1 0.50) |
| SGI: 0.90 (Revenue 339.0m / 378.4m) |
| TATA: -0.10 (NI 28.5m - CFO 67.7m) / TA 396.1m) |
| Beneish M-Score: -2.62 (Cap -4..+1) = A |
What is the price of IRWD shares?
Over the past week, the price has changed by -8.44%, over one month by -3.05%, over three months by +116.02% and over the past year by +110.90%.
Is IRWD a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IRWD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.9 | 9% |
| Analysts Target Price | 4.9 | 9% |
| ValueRay Target Price | 4.5 | 1.8% |
IRWD Fundamental Data Overview February 03, 2026
P/E Forward = 12.3305
P/S = 2.3467
P/B = 2.5899
P/EG = -0.26
Revenue TTM = 339.0m USD
EBIT TTM = 145.0m USD
EBITDA TTM = 146.9m USD
Long Term Debt = 385.0m USD (from longTermDebt, last quarter)
Short Term Debt = 202.7m USD (from shortTermDebt, last quarter)
Debt = 598.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 457.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.25b USD (795.5m + Debt 598.2m - CCE 140.4m)
Interest Coverage Ratio = 4.29 (Ebit TTM 145.0m / Interest Expense TTM 33.8m)
EV/FCF = 18.53x (Enterprise Value 1.25b / FCF TTM 67.6m)
FCF Yield = 5.40% (FCF TTM 67.6m / Enterprise Value 1.25b)
FCF Margin = 19.96% (FCF TTM 67.6m / Revenue TTM 339.0m)
Net Margin = 8.42% (Net Income TTM 28.5m / Revenue TTM 339.0m)
Gross Margin = 68.62% ((Revenue TTM 339.0m - Cost of Revenue TTM 106.4m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 99.45%)
Tobins Q-Ratio = 3.16 (Enterprise Value 1.25b / Total Assets 396.1m)
Interest Expense / Debt = 1.41% (Interest Expense 8.43m / Debt 598.2m)
Taxrate = 41.08% (27.9m / 68.0m)
NOPAT = 85.4m (EBIT 145.0m * (1 - 41.08%))
Current Ratio = 1.13 (Total Current Assets 273.8m / Total Current Liabilities 242.5m)
Debt / Equity = -2.26 (negative equity) (Debt 598.2m / totalStockholderEquity, last quarter -264.2m)
Debt / EBITDA = 3.12 (Net Debt 457.8m / EBITDA 146.9m)
Debt / FCF = 6.77 (Net Debt 457.8m / FCF TTM 67.6m)
Total Stockholder Equity = -301.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.27% (Net Income 28.5m / Total Assets 396.1m)
RoE = -9.46% (negative equity) (Net Income TTM 28.5m / Total Stockholder Equity -301.9m)
RoCE = 174.5% (EBIT 145.0m / Capital Employed (Equity -301.9m + L.T.Debt 385.0m))
RoIC = 30.26% (NOPAT 85.4m / Invested Capital 282.3m)
WACC = 5.78% (E(795.5m)/V(1.39b) * Re(9.50%) + D(598.2m)/V(1.39b) * Rd(1.41%) * (1-Tc(0.41)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.74%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈90.1m ; Y1≈59.2m ; Y5≈27.0m
Fair Price DCF = 2.47 (EV 860.0m - Net Debt 457.8m = Equity 402.2m / Shares 162.7m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -57.41 | EPS CAGR: -20.50% | SUE: -0.10 | # QB: 0
Revenue Correlation: -39.91 | Revenue CAGR: 1.11% | SUE: 2.89 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=+0.130 | Revisions Net=+2 | Analysts=2
EPS next Year (2026-12-31): EPS=0.85 | Chg30d=+0.393 | Revisions Net=+2 | Growth EPS=+234.6% | Growth Revenue=+37.2%